Evidence map›Paper›PMID 37628949›Full record

ReviewInternational journal of molecular sciences2023

MiRNA-146a-A Key Player in Immunity and Diseases.

Irina Gilyazova, Dilara Asadullina, Evelina Kagirova, Ruhi Sikka, Artur Mustafin, Elizaveta Ivanova, Ksenia Bakhtiyarova, Gulshat Gilyazova, Saurabh Gupta, Elza Khusnutdinova and 2 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 2 pooled it
20.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 2 syntheses or guidelines pooled it, 85 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Population-Specific Exploration ofInternational journal of molecular sciences · 2026
    Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Irina GilyazovaSubdivision of the Ufa Federal Research Centre of the Russian Academy of Sciences, Institute of Biochemistry and Genetics, 450054 Ufa, Russia.ORCID 0000-0001-9499-5632
Dilara AsadullinaInstitute of Urology and Clinical Oncology, Department of Medical Genetics and Fundamental Medicine, Bashkir State Medical University, 450008 Ufa, Russia.ORCID 0000-0003-4911-8037
Evelina KagirovaInstitute of Urology and Clinical Oncology, Department of Medical Genetics and Fundamental Medicine, Bashkir State Medical University, 450008 Ufa, Russia.
Ruhi SikkaDepartment of Biotechnology, Institute of Applied Sciences and Humanities, GLA University, Mathura 281406, India.
Artur MustafinInstitute of Urology and Clinical Oncology, Department of Medical Genetics and Fundamental Medicine, Bashkir State Medical University, 450008 Ufa, Russia.
Elizaveta IvanovaSubdivision of the Ufa Federal Research Centre of the Russian Academy of Sciences, Institute of Biochemistry and Genetics, 450054 Ufa, Russia.
Ksenia BakhtiyarovaInstitute of Urology and Clinical Oncology, Department of Medical Genetics and Fundamental Medicine, Bashkir State Medical University, 450008 Ufa, Russia.
Gulshat GilyazovaInstitute of Urology and Clinical Oncology, Department of Medical Genetics and Fundamental Medicine, Bashkir State Medical University, 450008 Ufa, Russia.ORCID 0000-0001-7189-5532
Saurabh GuptaDepartment of Biotechnology, Institute of Applied Sciences and Humanities, GLA University, Mathura 281406, India.
Elza KhusnutdinovaSubdivision of the Ufa Federal Research Centre of the Russian Academy of Sciences, Institute of Biochemistry and Genetics, 450054 Ufa, Russia.ORCID 0000-0003-2987-3334
Himanshu GuptaDepartment of Biotechnology, Institute of Applied Sciences and Humanities, GLA University, Mathura 281406, India.ORCID 0000-0003-1391-8358
Valentin PavlovInstitute of Urology and Clinical Oncology, Department of Medical Genetics and Fundamental Medicine, Bashkir State Medical University, 450008 Ufa, Russia.
Bashkir State Medical University · RUGLA University · INUfa Institute of Chemistry · RU

Funding

Ministry of Science and Higher Education of the Russian Federation 075-15-2021-595Ministry of Science and Higher Education of the Russian Federation Bashkir State Medical University Strategic Academic Leadership Program (PRIORITY-2030)
6 · The paper itself

Abstract

miRNA-146a, a single-stranded, non-coding RNA molecule, has emerged as a valuable diagnostic and prognostic biomarker for numerous pathological conditions. Its primary function lies in regulating inflammatory processes, haemopoiesis, allergic responses, and other key aspects of the innate immune system. Several studies have indicated that polymorphisms in miRNA-146a can influence the pathogenesis of various human diseases, including autoimmune disorders and cancer. One of the key mechanisms by which miRNA-146a exerts its effects is by controlling the expression of certain proteins involved in critical pathways. It can modulate the activity of interleukin-1 receptor-associated kinase, IRAK1, IRAK2 adaptor proteins, and tumour necrosis factor (TNF) targeting protein receptor 6, which is a regulator of the TNF signalling pathway. In addition, miRNA-146a affects gene expression through multiple signalling pathways, such as TNF, NF-κB and MEK-1/2, and JNK-1/2. Studies have been carried out to determine the effect of miRNA-146a on cancer pathogenesis, revealing its involvement in the synthesis of stem cells, which contributes to tumourigenesis. In this review, we focus on recent discoveries that highlight the significant role played by miRNA-146a in regulating various defence mechanisms and oncogenesis. The aim of this review article is to systematically examine miRNA-146a's impact on the control of signalling pathways involved in oncopathology, immune system development, and the corresponding response to therapy.

Indexed as

Autoimmune DiseasesMicroRNAsAdaptor Proteins, Signal TransducingCarcinogenesisCell Transformation, NeoplasticHumansAdaptor Proteins, Signal TransducingMicroRNAscancerimmunitymiRNAmiRNA-146a

Identifiers

PMID37628949
PMCPMC10454149
OpenAlexW4385895882

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.